Ignite Creation Date:
2025-12-24 @ 3:17 PM
Ignite Modification Date:
2025-12-25 @ 2:27 PM
Study NCT ID:
NCT00591292
Status:
UNKNOWN
Last Update Posted:
2012-07-19
First Post:
2007-12-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Study in Advanced Solid Tumors
Sponsor:
Alaunos Therapeutics
Organization:
Study Overview
Official Title:
IBL1002:Phase I Study of Indibulin in Advanced Solid Tumors
Status:
UNKNOWN
Status Verified Date:
2012-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dose escalating study of orally administered indibulin at twice daily schedule in subjects with solid tumors.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: